THE WOODLANDS, Texas,
Nov. 9, 2011 /PRNewswire/ -- Lexicon
Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company
focused on discovering breakthrough treatments for human disease,
announced today that Dr. Roy
Fleischmann from the University of
Texas Southwestern Medical Center will be presenting data
from Lexicon's LX2931 Phase 2 proof-of-concept clinical trial at
the annual meeting of the American College of Rheumatology on
Wednesday, November 9, 2011 in
Chicago, Illinois. LX2931 is
an orally-administered small molecule designed to inhibit
sphingosine-1-phosphate lyase (S1P), an enzyme in a pathway known
to be important in regulating the immune response.
Results from the Phase 2a study demonstrated a favorable safety
profile at all doses tested and suggested that patients with
rheumatoid arthritis treated with 150 mg of LX2931 once daily
showed improvement in the primary efficacy endpoint of the study,
the percentage of patients achieving an American College of
Rheumatology 20 (ACR20) response at week 12.
For more information on this program or to download a copy of
the presentation, please visit www.lexpharma.com.
About Lexicon
Lexicon is a biopharmaceutical company focused on discovering
breakthrough treatments for human disease. Lexicon currently
has four drug programs in mid-stage development for diabetes,
irritable bowel syndrome, carcinoid syndrome and rheumatoid
arthritis, all of which were discovered by Lexicon's research team.
Lexicon has used its proprietary gene knockout technology to
identify more than 100 promising drug targets. Lexicon has
focused drug discovery efforts on these biologically-validated
targets to create its extensive pipeline of clinical and
preclinical programs. For additional information about
Lexicon and its programs, please visit www.lexpharma.com.
Safe Harbor Statement
This press release contains "forward-looking statements,"
including statements relating to Lexicon's clinical development
of LX2931, including characterizations of the results of and
projected timing of clinical trials of LX2931, and the potential
therapeutic and commercial potential of LX2931. This press
release also contains forward-looking statements relating to
Lexicon's growth and future operating results, discovery and
development of products, strategic alliances and intellectual
property, as well as other matters that are not historical facts or
information. All forward-looking statements are based on
management's current assumptions and expectations and involve
risks, uncertainties and other important factors,
specifically including those relating to Lexicon's ability to
successfully conduct clinical development of LX2931 and preclinical
and clinical development of its other potential drug candidates,
advance additional candidates into preclinical and clinical
development, obtain necessary regulatory approvals, achieve its
operational objectives, obtain patent protection for its
discoveries and establish strategic alliances, as well as
additional factors relating to manufacturing, intellectual property
rights, and the therapeutic or commercial value of its drug
candidates, that may cause Lexicon's actual results to be
materially different from any future results expressed or implied
by such forward-looking statements. Unless specifically
indicated otherwise, results were not statistically significant.
Information identifying such important factors is contained under
"Risk Factors" in Lexicon's annual report on Form 10-K for the year
ended December 31, 2010, as filed
with the Securities and Exchange Commission. Lexicon
undertakes no obligation to update or revise any such
forward-looking statements, whether as a result of new information,
future events or otherwise.
SOURCE Lexicon Pharmaceuticals, Inc.